IDH1 and glioblastoma: Chaurasia et al. [22] further categorized glioblastoma patients into three prognostic subgroups based on these markers: group 1: lacking both IDH1 mutation and TP53 expression; group 2: possessing IDH1 mutation and ATRX loss; group 3: having IDH1 mutation but lacking TP53 expression.